[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dasman Diabetes Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":208},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,65,93,119,153,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100637988","tirzepatide-titration-to-reduce-side-effects-in-individuals-with-obesity-100637988",false,"NCT07574723","Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity","Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity","TiTRE","Inclusion Criteria:\n\n1. Adults aged 18 years and older\n2. A diagnosis of obesity (BMI ≥ 27 kg\u002Fm2) at screening with self-reported unsuccessful dietary efforts to lose weight.\n3. No diagnosis of diabetes mellites.\n4. Able to understand and sign the consent form\n5. Able to undergo DEXA scan.\n\nExclusion Criteria:\n\n* 1\\. History of type 1 or type 2 diabetes mellites. 2. Obesity-related:\n\n  * A self-reported change in body weight \\>5 kg (11 lbs) within 90 days before screening irrespective of medical records.\n  * Treatment with any medication for the indication of obesity within the past 90 days before screening.\n  * Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and\u002For abdominoplasty, if performed \\>1 year before screening; (2) lap banding, if the band has been removed \\>1 year before screening; (3) intragastric balloon, if the balloon has been removed \\>1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \\>1 year before screening.\n  * Uncontrolled thyroid disease, defined as thyroid stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL as measured by the central laboratory at screening.\n\n    3\\. Mental health:\n  * History of major depressive disorder within 2 years before screening.\n  * Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).\n  * A Patient Health Questionnaire-9 score of ≥15 at screening.\n  * A lifetime history of a suicidal attempt.\n  * Suicidal behavior within 30 days before screening. 4. General safety:\n  * Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown\u002Funspecified content within 90 days before screening.\n  * Presence of acute pancreatitis within the past 180 days prior to the day of screening.\n  * History or presence of chronic pancreatitis.\n  * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n  * Renal impairment measured as estimated glomerular filtration rate value of \\\u003C15 mL\u002Fmin\u002F1.73 m2 as defined by KDIGO 2012 by the central laboratory at screening.\n  * History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n  * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.\n  * Subject presently classified as being in New York Heart Association Class IV.\n  * Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.\n  * Known or suspected abuse of alcohol or recreational drugs.\n  * Known or suspected hypersensitivity to trial product(s) or related products.\n  * Previous participation in this trial. Participation is defined as signed informed consent.\n  * Participation in another clinical trial within 90 days before screening.\n  * Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.\n  * Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","ALL","18 Years","100 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. The main questions it aims to answer are:\n\n1. Does flexible, symptom-guided titration reduce nausea and vomiting compared with standard per-label titration?\n2. Does flexible titration achieve weight loss comparable to standard titration?\n\nResearchers will compare standard per-label titration with a click-based, symptom-guided titration approach to assess differences in tolerability and treatment effectiveness.\n\nParticipants will:\n\n* Be randomly assigned to standard or flexible tirzepatide titration\n* Use a click-based dosing method that allows small dose increases based on tolerability (flexible group)\n* Attend study visits over 76 weeks for safety and outcome assessments\n\nThis study addresses the lack of evidence for individualized titration strategies in obesity treatment and aims to improve tolerability, adherence, and long-term treatment outcomes.",[28],"Obesity","NOT_YET_RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":22},"2026-05-15",{"date":37,"type":22},"2029-12-31",{"name":39,"class":40},"Dasman Diabetes Institute","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":64},"100584161","lean-mass-preservation-with-resistance-exercise-and-protein-during-semaglutidetirzepatide-therapy-100584161","NCT06885736","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide\u002FTirzepatide Therapy","LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide and Tirzepatide Therapy (LEAN-PREP Study)","LEAN-PREP","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years\n* BMI \\>\u002F= 27 kg\u002Fm2\n\nExclusion Criteria:\n\n* Currently or in the past 6 months participating in any vigorous aerobic activity (\\>1h per week) or any resistance exercise.\n* BP of 160\u002F100mmHg or higher\n* Any known medical condition that prevents participants from exercising safely\n* A personal or family history of medullary thyroid carcinoma\n* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n* History of chronic or acute pancreatitis\n* History of proliferative diabetic retinopathy or diabetic maculopathy\n* History of ketoacidosis or hyperosmolar state\u002Fcoma\n* History of severe hypoglycaemia and\u002For hypoglycaemia unawareness within last 6 months\n* Clinically significant gastric emptying abnormality or have undergone or plan to undergo gastric bypass or restrictive bariatric surgery or chronically taking drugs that directly affect GI motility\n* Any of the following CV conditions in last 2 months: acute MI, stroke or hospitilisation due to CHF\n* History of NYHA IV CHF\n* Acute or chronic hepatitits, signs and symptoms of any liver disease other than NAFLD, ALT \\> 3 times the upper limit of normal\n* eGFR \\\u003C45mL\u002Fmin\u002F1.73m2\n* Significant uncontrolled endocrine abnormaility in the opinion of clinical investigator\n* Evidence of active autoimmune abnormality that is likely to requite systemic glucocorticoid treatment in the next 12 months\n* Had or waiting for an organ transplant\n* History of an active or untreated malignancy or in remission from a clinically significant malignancy for less than 5 years\n* Any other aspect of history or condition that may limit the ability of the patient to complete the study\n* Having been treated with prescription drugs that promote weight loss in the last 3 months\n* Receiving chronic systemic glucocorticoid therapy within last month",{"count":50,"type":22},232,[25],"The aim of the current study is to determine whether resistance exercise and\u002For protein intake can preserve lean mass and improve physical function in patients with obesity initiating semaglutide\u002Ftirzepatide therapy. To achieve this aim the study will have the following objectives.\n\nIn people with obesity initiating semaglutide\u002Ftirzepatide therapy\n\n1. Form a PPI group to refine the study protocol and establish study materials,\n2. Quantify the effects of a pragmatic resistance exercise intervention and\u002For increasing protein intake on lean mass and physical function during semaglutide\u002Ftirzepatide induced weight loss,\n3. Establish whether the resistance exercise intervention and\u002For increasing protein intake has concomitant benefits on glycaemic control, lipids, liver function, quality of life, physical activity and sleep during semaglutide\u002Ftirzepatide induced weight loss.\n\nThe participants will:\n\nBegin their weight loss medication, starting at a low dose and then increasing the dose to maximize weight loss. They will be randomly assigned by a computer to ONE of the following groups and will be followed up to 6-months:\n\n* Control group\n* Protein intake group\n* Muscle strengthening exercise group\n* Muscle strengthening exercise AND protein intake group.",[28],[55],"Obesity, research","RECRUITING","2026-04-19",{"date":59,"type":33},"2026-04-21",{"date":61,"type":33},"2025-08-07",{"date":37,"type":22},{"name":39,"class":40},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":64},"100600393","phase-4-tirzepatide-use-in-people-with-obesity-and-type-1-diabetes-100600393","NCT07096908","Tirzepatide Use in People With Obesity and Type 1 Diabetes","Treatment With Tirzepatide of the Disease of Obesity in People With Type 1 Diabetes","Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities.\n2. Male or female, adults.\n3. Documented diagnosis of T1DM (per ADA 2024definition\u002Fcriteria) for at least 1 year before screening visit with C-peptide level of less than 0.01nm\u002FL.\n4. Body mass index (BMI) ≥ 27.0 kg\u002Fm2\n5. History of at least one self-reported unsuccessful dietary effort to lose body weight.\n6. Must be using a Continuous Glucose Monitoring (CGM) device for at least 2 months before the screening visit and be willing to wear a CGM device for the duration of the study.\n\nExclusion Criteria:\n\n1. Diabetes related:\n\n   * Glycated hemoglobin (HbA1c) ≥86 mmol\u002Fmol (10%) as measured by the central laboratory at screening.\n   * Treatment with a glucagon-like peptide-1 receptor agonist within 180 days before screening.\n   * Preproliferative or proliferative retinopathy\n   * Experienced diabetic ketoacidosis within 6 months of screening visit.\n   * Experienced severe hypoglycemia (Level 3) within 6 months of screening visit.\n2. Obesity-related:\n\n   * A self-reported change in body weight \\>5 kg (11 lbs) within 90 days before screening irrespective of medical records.\n   * Treatment with any medication for the indication of obesity within the past 90 days before screening.\n   * Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and\u002For abdominoplasty, if performed \\>1 year before screening; (2) lap banding, if the band has been removed \\>1 year before screening; (3) intragastric balloon, if the balloon has been removed \\>1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \\>1 year before screening.\n   * Uncontrolled thyroid disease, defined as thyroid stimulating hormone \\>6.0 mIU\u002FL or \\\u003C0.4 mIU\u002FL as measured by the central laboratory at screening.\n3. Mental health:\n\n   * History of major depressive disorder within 2 years before screening.\n   * Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).\n   * A Patient Health Questionnaire-9 score of ≥15 at screening.\n   * A lifetime history of a suicidal attempt.\n   * Suicidal behavior within 30 days before screening.\n   * Suicidal ideation corresponding to type 4 or 5 on the Columbia-Suicide Severity Rating Scale within the past 30 days before screening.\n4. General safety:\n\n   * Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown\u002Funspecified content within 90 days before screening.\n   * Presence of acute pancreatitis within the past 180 days prior to the day of screening.\n   * History or presence of chronic pancreatitis.\n   * Calcitonin ≥100 ng\u002FL as measured by the central laboratory at screening.\n   * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.\n   * Renal impairment measured as estimated glomerular filtration rate value of \\\u003C15 mL\u002Fmin\u002F1.73m2 as defined by KDIGO 2012 by the central laboratory at screening.\n   * History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n   * Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.\n   * Subject presently classified as being in New York Heart Association Class IV.\n   * Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.\n   * Known or suspected abuse of alcohol or recreational drugs.\n   * Known or suspected hypersensitivity to trial product(s) or related products.\n   * Previous participation in this trial. Participation is defined as signed informed consent.\n   * Participation in another clinical trial within 90 days before screening.\n   * Other subject(s) from the same household participating in any semaglutide trial.\n   * Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.\n   * Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","21 Years",{"count":74,"type":22},60,[76],"PHASE4","Tirzepatide, a gut hormone-based medication, has shown promising results in treating obesity, with \\~22% weight loss and mild side effects. However, patients with type 2 diabetes typically experience only about 15% weight loss with tirzepatide, despite tolerating the medication well. Its effects in people with both obesity and type 1 diabetes remain largely unknown.\n\nAlthough tirzepatide is not approved for glycemic control in type 1 diabetes, it is licensed for obesity treatment in Gulf and Europe. In Kuwait, more than a quarter of people with type 1 diabetes also have obesity, presenting a unique opportunity to study tirzepatide's impact.\n\nThis randomized, double-blind controlled trial will evaluate the safety and efficacy of tirzepatide in patients with type 1 diabetes and obesity, comparing usual care with the maximum tolerable dose of tirzepatide to assess its impact on weight loss. The findings may help address important safety concerns and have the potential to inform and influence future clinical practice.",[79,28],"Type1diabetes",[81,82,83,84],"T1D","tirzepatide","weight loss","obesity","2026-04-15",{"date":87,"type":33},"2026-04-20",{"date":89,"type":33},"2025-07-31",{"date":91,"type":22},"2028-08-01",{"name":39,"class":40},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100586997","phase-4-can-the-addition-of-pioglitazone-to-sglt2-inhibitor-in-type-1-diabetic-patients-amplify-the-decrease-in-hba1c-and-prevent-the-increase-in-plasma-ketone-concentration-100586997","NCT06922656","Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","Inclusion Criteria:\n\n\\- 1) Age \\>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.\n\n4\\) Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U\u002Fkg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml\u002Fmin. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program\n\nExclusion Criteria:\n\n* 1\\) Age \\>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.\n\n  4\\) Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U\u002Fkg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml\u002Fmin. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program",{"count":74,"type":22},[76],"Previous data from our clinical trial has demonstrated that the combination of dapagliflozin plus pioglitazone cause robust decrease in the plasma glucose concentration without significant increase in plasma ketone concentration in subjects with T1DM receiving multiple insulin injections or insulin pump. Although patients receiving insulin therapy with pump have participated in the study, none has insulin delivered in automated pump (780 pump) which automatically adjusts the rate of insulin infusion based upon the measured plasma glucose concentration. Although automated insulin pumps have been introduced to practice only last year, they are gaining popularity in the care of T1DM patients worldwide. The aim of this amendment is to demonstrate the efficacy (decrease in HbA1c) and safety (no significant increase in plasma ketone concentration) of combination of dapagliflozin plus pioglitazone in T1DM patients receiving insulin therapy with automated insulin pump.",[103],"Type 1 Diabetes",[105,106,107,108,109],"Ketoacidosis","Hypoglycemia","Glucose Control","SGLT2 Inhibitors","Pioglitazone","2025-08-24",{"date":112,"type":33},"2025-08-29",{"date":114,"type":22},"2025-09-15",{"date":116,"type":22},"2027-01-15",{"name":39,"class":40},3,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":64},"100591723","structured-education-program-and-glycemic-control-in-adolescents-with-type-1-diabetes-100591723","NCT06984133","Structured Education Program and Glycemic Control in Adolescents With Type 1 Diabetes","Evaluating the Effectiveness of a Structured Educational Program on Glycemic Control in Adolescents With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Arab adolescents\n* Males and females aged 11 to 14 years.\n* Have been diagnosed with type 1 diabetes for at least 6 months.\n* Wearing a continuous glucose monitor (CGM).\n* Individuals and their parents must be able to join the entire duration of the study.\n* Individuals and their parents must voluntarily provide consent and assent.\n\nExclusion Criteria:\n\n* Presence of learning disabilities or any known psychological issues.\n* Attendance at any diabetes education or carbohydrate counting programs within the six months preceding the study.","11 Years","14 Years",{"count":129,"type":22},128,[25],"Type 1 diabetes is becoming more common in Kuwaiti and Arab adolescents. Many young people with this condition struggle to keep their blood glucose levels under control, which can lead to diabetes-related complications and affect their quality of life.\n\nThe goal of this clinical trial is to evaluate the effectiveness of a structured educational program on glycemic control among Arab adolescents with type 1 diabetes aged 11 to 14 years.\n\nParticipants will be randomly assigned to one of two groups. The intervention group will receive the structured education program, and the control group will continue with standard care.\n\nAll participants will undergo assessments that include:\n\n* collecting demographic and diabetes management data\n* measuring weight and height\n* measuring HbA1c levels and lipid profile\n* filling out questionnaires on quality of life, carbohydrate and insulin dosing knowledge, physical activity\n* collecting dietary intake\n* providing AGP report\n\nParticipants in the intervention group will additionally be required to:\n\n* attend the program for 4 consecutive days, one day for parents and three days for children\n* fill out 3-day food diary records during the program\n* attend a refresher course after 6 months\n\nParticipants in the control group will have the opportunity to participate in the program after approximately six months.",[133,134],"Type 1 Diabetes (T1D)","Type 1 Diabetes Mellitus (T1DM)",[136,137,138,139,140,141,142,143,144],"Kuwait","Glycemic control","Type 1 diabetes","Carbohydrate counting","Arab adolescents","Structured education","Adolescents","Diabetes education program","HbA1c","2025-05-14",{"date":147,"type":33},"2025-05-22",{"date":149,"type":22},"2025-05-18",{"date":151,"type":22},"2028-05-18",{"name":39,"class":40},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":64},"100564715","a-pilot-study-to-assess-the-impact-of-breath-awareness-using-pyramid-on-symptoms-of-anxiety-and-depression-in-people-with-t2dm-100564715","NCT06632782","A Pilot Study to Assess the Impact of Breath Awareness Using Pyramid on Symptoms of Anxiety and Depression in People with T2DM","BAPD","Inclusion Criteria: • More than 1 year of T2DM diagnosis\n\n* T2DM with HbA1c greater than 5.7 and less than 9.5%\n* T2DM patients, age greater than 30 years and on oral hypoglycaemic agents or on insulin\n* No cardiac problems\n* Score 8.0 and above as per the anxiety and depression questionnaires.\n* Able to be aware of breath and provide written informed consent.\n\nExclusion Criteria:\n\n* T1DM patients\n* On antidepressant drugs\n* Bipolar disorders\n* Any acute coronary events in the past 6 months\n* Any acute renal diseases including transplant or dialysis.\n* Artificial pacemaker\n* Any breath awareness or yoga course within 6 months.\n* Pregnancy","30 Years","80 Years",{"count":163,"type":22},152,[25],"Diabetes mellitus is rampant in the Middle East. It is a psychologically and behaviorally demanding disease; psychosocial factors are relevant to nearly all aspects of its management. Moreover, depression and diabetes are bidirectionally connected. Those with depression are at risk of developing diabetes and those with comorbid diabetes are at risk of developing depressive symptoms. Research findings have demonstrated that depression and anxiety are more common in patients with diabetes than in the general population, atleast 15 % have clinical depression. In addition, the recent COVID- 19 pandemic has fueled the burden by increasing fear, anxiety, and depression among people with T2DM due to susceptibility to long-term complications. In Kuwait, a recent survey found the prevalence of depression to be 29% and diabetes distress to be 14%. Thus, there is a dire need to address this challenging problem. In the recent past, mindfulness-based intervention such as Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT,) and yoga have emerged as unique tools for reducing a wide range of psychological disorders. These tools positively impact hormone regulation and have a beneficial effect on cognitive function and increased parasympathetic activity. The positive impact of mindfulness is assumed to be amplified if a pyramid structure with geometry similar to the pyramid of Giza is used for practice. Not much human research has been performed to demonstrate that pyramid energy along with mindfulness can be a tool to combat psychological disorders. However, few studies on animal models provided evidence of the potential beneficial effect of pyramid structure in reducing stress. Previous pilot study conducted using only yoga as an intervention indicated significant improvement in anxiety, depression, and quality of life in people with T2DM. However, there was no change in participants' glycemic control. In this pilot study, investigator will assess whether pyramid breath awareness can alleviate symptoms of depression and anxiety in people with T2DM.",[167],"Depression, Anxiety",[169],"depression","2024-10-16",{"date":172,"type":33},"2024-10-18",{"date":174,"type":22},"2024-11-01",{"date":176,"type":22},"2026-12-31",{"name":39,"class":40},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":17,"minAge":72,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":64},"100524987","kuwait-adult-diabetes-epidemiological-multidisciplinary-kadem-program-100524987","NCT06115876","Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program","KADEM","Inclusion Criteria:\n\nPeople who participated in the original KDEP study. People with prediabetes. Type 2 Diabetes patients.\n\nExclusion Criteria:\n\nPeople are unwilling to sign the consent form. Pregnant women.",true,"75 Years",{"count":188,"type":22},2000,"OBSERVATIONAL","Kuwait and the Gulf Region lack large longitudinal studies that identify risk factors dictating the onset of prediabetes and the progression to diabetes. The Kuwait Diabetes Epidemiology Program (KDEP), previously carried out at Dasman Diabetes Institute, was designed to develop a research dataset providing a random sampling of the Kuwaiti population. The dataset contained primarily epidemiology data for healthy, prediabetic and diabetic individuals; and was designed to serve as a resource for research and prevention programs on obesity, diabetes, and metabolic syndrome. The KDEP data supported research studies at DDI to delineate risk factors for metabolic disease from the views of genetics, biochemistry, immunology and epidemiology. One of the main limitations of the KDEP study was that it only captured a cross-sectional view of the participants in terms of diabetes status as well as lack of extensive phenotyping. In the current study, the investigators aim to perform a follow up on the non-diabetic KDEP cohort participants to enrich it with detailed physiological, genetic, biochemical and environmental data and thereby to establish an association between the development of diabetes and multidimensional risk factors. the investigatorswill also recruit family members of the KDEP and RA2010-005 participants as well as others with family history of diabetes to better identify familial patterns in risk factors. The outcome of this effort will immediately serve as a scientific baseline for developing prevention strategies for the control and management of obesity, diabetes and associated complications such as cardiovascular disease. Given the magnitude of the social and economic burden of diabetes on the Kuwaiti population, longitudinal data from the KDEP Follow-up study should play an important role in establishing the incidence of T2D progression in non-diabetic participants that were enrolled in the initial study as well as of progression to diabetes complications. This will have a positive impact on the population by providing clinicians with data to better target their patient management and by supporting policy and decision-makers in developing comprehensive health promotion programs to control these diseases at the national level.",[192,193,194],"Diabetes Mellitus Type 2, Diabetes Mellitus Type 1","NAFLD - Nonalcoholic Fatty Liver Disease","PreDiabetes",[196,136,197,39,198,199],"Prediabetes","KFAS","Diabetes Prevention","NAFLD","2023-10-30",{"date":202,"type":33},"2023-11-03",{"date":204,"type":33},"2022-05-23",{"date":206,"type":22},"2027-05-23",{"name":39,"class":40},""]